Company Overview of Intas Pharmaceuticals Ltd.
Intas Pharmaceuticals Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company offers pharmaceutical products for various therapeutic areas, including neurology, psychiatry, cardiology, pain management, gastroenterology, diabetology, nephrology, urology, anti-infective therapy, dermatology, gynecology, respiratory system, hematology, and ophthalmology, as well as chronic therapy areas relating to neurology, psychiatry, cardiology, and diabetology; and Rituximab, a drug to treat Non-Hodgkin's Lymphoma (a type of blood cancer). The company also engages in in-licensing a lipid-based new drug delivery system platform for developing and commercializi...
Off Nehru Bridge
Founded in 1985
Key Executives for Intas Pharmaceuticals Ltd.
Chief Executive Officer, Managing Director, Director, Member of Share Allotment Cum Transfer Committee, Member of Investor Grievance Committee and Member of IPO Committee
Chief Finance Officer, Member of Share Allotment cum Transfer Committee and Member of IPO Committee
President of Accord Healthcare Inc.
President (U S A) of Accord Healthcare Incorporated
Compensation as of Fiscal Year 2015.
Intas Pharmaceuticals Ltd. Key Developments
Intas Pharmaceuticals Launches Biosimilar Version of Ranibizumab in India
Jun 24 15
Intas Pharmaceuticals announced that it has launched a "biosimilar" version of Roche's Lucentis (ranibizumab) in India. The biosimilar is marketed under the brand name Razumab and will reportedly be sold at a discount of some 25% against imported Lucentis. Lucentis is indicated for the treatment of wet age-related macular degeneration, macular oedema following retinal vein occlusion, and diabetic macular oedema. It remains unclear, however, for which of these indication Razumab is indicated. Significance:With details of the pathway used for the approval and the clinical data used to support its application remaining limited it is challenging to determine if Razumab is a biosimilar - i.e. in line with the definition of biosimilars in regulated markets. The company currently markets a growing portfolio of biosimilar products in India, including biosimilar erythropoietin, filgrastim, pegylated filgrastim, and rituximab. Launching in regulated markets does however require significant finances to conduct the clinical research needed to support market access and the marketing know-how to support market uptake once approved. Despite these challenges the company has launched a biosimilar version of Amgen's Neupogen (filgrastim) in Europe. It is important to note that the clinical data and marketing knowledge needed to launch a monoclonal antibody is substantially more significant than that needed to launch a less complex biologic such as filgrastim. In India, even with a 25% discount, the biosimilar may be out of reach for many in India's largely out-of-pocket market. This point, coupled with a preference for western brands among the wealthy, means that the market potential for Razumab in India may be limited.
Intas Launches Biosimilar Version of Amgen's Neupogen in Europe
Feb 24 15
Intas has launched a biosimilar version of Amgen's (US) neutropaenia drug Neupogen (filgrastim). The injectable drug is the first biosimilar manufactured by an Indian company to be approved in the tightly regulated EU market. According to a company statement, Phase III clinical trials (multi-centre safety and efficacy studies involving 120 female adult patients receiving chemotherapy to treat breast cancer) showed that Intas's filgrastim reduced severe neutropaenia to 1.4 days from an average of 1.6 and 1.8 days reported in other studies. Intas has confirmed that its lower-cost version of filgrastim, marketed under the brand name Accofil, has secured UK and Dutch tendering contracts, and expects to launch in Mexico and Brazil in the next six months. The company is looking to file for US approval in 2016, but would face competition at launch from Sandoz (subsidiary of Swiss firm Novartis), which has already filed for approval for Zarxio, another biosimilar version Neupogen. It is anticipated that the US FDA is likely to make a final decision regarding the approval of Zarxio in March.
Investors Reportedly Eyes Stake In Intas
Jan 29 14
Temasek Capital, GIC Pte. Ltd., and Capital International, Inc. are in independent talks to purchase ChrysCapital's 10% stake in Intas Pharmaceuticals Ltd. for about $150 million, three people with direct knowledge of the development said. An investment banker said, "Chrys-Capital is looking to sell part of its 16.5% stake after Intas Pharma postponed its initial public offering due to muted market conditions." "Yes, ChrysCapital is looking for partial exit from the company and the IPO plan was also formulated with the objective of providing exit," Jayesh Shah, Chief Financial Officer of Intas Pharma said in an email response. "However, Intas is still evaluating various options to provide meaningful exit to ChrysCapital and nothing has been concretised so far." Another person familiar with the matter said, "Along with the partial exit of the existing investor, the promoters could look at raising fresh funds for the company." "No valuation number has been frozen," said Shah of Intas.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 2, 2014